Get to know and reach out to the experts at Profil.

Short Bio

Leona has profound scientific and medical expertise in the field of obesity, diabetes, and metabolism. She has a strong background of research in both academic and industry environments with particular know-how in in basic science in molecular endocrinology and energy metabolism as well as translational clinical research and early-phase clinical development for obesity and diabetes.

Additionally, she is experienced in the development process of bioactive food compounds for nutraceutical applications. Prof. Dr. Plum-Mörschel is an active academic lecturer and member in both diabetes- and endocrinology-related professional scientific societies. In combination with the unique experience in diabetes and cardio-metabolic research, the expertise in nutritional sciences and the availability of a metabolic ward at Profil, the Obesity & Prediabetes Department facilitates the design and conduct of intelligent and comprehensive clinical trials focusing on body adiposity, either as a primary focus or as a means to improve glycemic control, metabolic disease risk, or other significant comorbidities.

Publications

Here are Leona's recent publications:

• Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Palle MS, Vogl T, Loomba R, Plum-Mörschel L.
  Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.
  ALIMENT PHARMACOL THER 2021 Sep 27. doi:10.1111/apt.16608. Online ahead of print.

• Pieber TR, Aronson R, Hövelmann U, Willard J, Plum-Mörschel L, Knudsen KM, Bandak B, Tehranchi R.
  Dasiglucagon: A next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia. Results of phase 3 randomized double-blind clinical trial.
  DIABETES CARE 44: 1-7, 2021. 

• Leohr J, Dellva MA, LaBell E, Coutant DE, Klein O, Plum-Moerschel L, Zijlstra E, Linnebjerg H.
  Pharmacokinetic and glucodynamic responses of ultra rapid lispro vs lispro across a clinically relevant range of subcutaneous doses in healthy subjects.
  Clin Ther 42: 1762-1777, 2020

• Bergougnan L, Andersen G, Plum-Mörschel L, Evaristi MF, Poirier B, Tardat A, Ermer M, Herbrand T, Arrubla J, Coester HV, Sansone R, Heiss C, Vitse O, Hurbin F, Boiron R, Benain X, Radzik D, Janiak P, Muslin AJ, Hovsepian L, Kirkesseli S, Deutsch P, Parkar AA. Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial. Br J Clin Pharmacol 2020 Oct 30. doi: 10.1111/bcp.14632. Online ahead of print
• Andersen G, Plum-Mörschel L, Hockings PD, Morsing A, Palle MS, Svolgaard O, Flint A.
  Clinical characteristics of a non-alcoholic fatty liver disease population across the fibrosis spectrum measured by magnetic resonance elastography: Analysis of screening data.
  Adv Ther 2020 Oct 1. doi: 10.1007/s12325-020-01503-x. Online ahead of print

• Linnebjerg H, Zhang Q, LaBell E, Dellva MA, Coutant DE, Hövelmann U, Plum-Mörschel L, Herbrand T, Leohr J.
  Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog (lispro) in younger adults and elderly patients with type 1 diabetes mellitus: A randomised controlled trial.
  CLIN PHARMACOKINET 2020 May 29. doi: 10.1007/s40262-020-0093-0. Online ahead of print

• Suico JG, Hövelmann U, Zhang S, Shen T, Bergman B, Sherr J, Zijlstra E, Frier BM, Plum-Mörschel L.
  Glucagon administration by nasal and intramuscular routes in adults with type 1 diabetes during insulin-induced hypoglycaemia: A randomised, open-label, crossover study.
  DIABETES THER 2020 Jun 8. doi: 10.1007/s13300-020-00845-7. Online ahead of print
• Parker VER, Robertson D, Wang T, Hornigold DC, Petrone M, Cooper AT, Posch MG, Heise T, Plum-Moerschel L, Heike S, Klaus B, Ambery PD, Meier JJ, Hirshberg B.
  Efficacy, safety, and mechanistic insights of cotadutide a dual receptor glucagon-like peptide-1 and glucagon agonist.
  J CLIN ENDOCRINOL METAB 2019 Oct 14. doi: 10.1210/clinem/dgz047. (Epub ahead of print)
• Halberg IB, Lyby K, Wassermann K, Heise T, Plum-Mörschel L, Zijlstra E.
  The effect of food intake on the pharmacokinetics of oral basal insulin: A randomised crossover trial in healthy male subjects.
  CLIN PHARMACOKINET 2019 May 16. doi: 10.1007/s40262-019-00772-2. (Epub ahead of print)
• Meiffren G, Herbrand T, Anastassiadis E, Klein O, DeVries JH, Heise T, Alluis B, Megret C, Gaudier M, Soula O, Plum-Mörschel L.
  Better glycemic control with BioChaperone Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM).
  DIABETES OBES METAB 2019 Mar 3. doi: 10.1111/dom.13685. (Epub ahead of print)
• Halberg IB, Lyby K, Wassermann K, Heise T, Zijlstra E, Plum-Mörschel L.
  Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.
  LANCET DIABETES ENDOCRINOL 2019 Jan 21. doi: 10.1016/S2213-8587(18)30372-3. (Epub ahead of print)
• Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L.
  MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
  Lancet 2018 Jun 30; 391: 2607-2618. 
• Forst T, Alghdban MK, Fischer A, Weber MM, Voswinkel S, Heise T, Kapitza C, Plum-Mörschel L.
  Sequential treatment escalation with dapagliflozin and saxagliptin improves beta cell function in type 2 diabetic patients on previous metformin treatment: An exploratory mechanistic study.
  HORM METAB RES 2018 May 4. doi: 10.1055/a-0591-9442. (Epub ahead of print)
• Zijlstra E, Coester HV, Heise T, Plum-Mörschel L, Rasmussen O, Rikte T, Pedersen LK, Qvist M, Sparre T.
  Injecting without pressing a button: An explanatory study of a shield-triggered injection mechanism.
  DIABETES OBES METAB 2017 Dec 27. doi: 10.1111/dom.13203. (Epub ahead of print)
• Harris C, Forst T, Heise T, Plum-Mörschel L, Watkins E, Zhang Q, Fan L, Garhyan P, Porksen N.
  Hypoglycemia risk related to double dose is markedly reduced with basal insulin peglispro versus insulin glargine in patients with type 2 diabetes mellitus in a randomized trial: IMAGINE 8.
  DIABETES TECHNOL THER 19: 463-470, 2017
• Forst T, Plum-Mörschel L, Weber MM.
  Cardiovascular aspects of diabetes treatment: Finally a reason for cardiologists to be pleased.
  INTERNIST (Berl.) 2017 Jan 24. doi: 10.1007/s00108-017-0189-0. (Epub ahead of print). (German)
• Forst T, Falk A, Andersen G, Fischer A, Weber MM, Voswinkel S, Heise T, Kapitza C, Plum-Mörschel L.
  Effects on alpha- and beta-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
  DIABETES OBES METAB 19: 489-495, 2017
• Porksen N, Linnebjerg H, Garhyan P, Lam ECQ, Knadler MP, Jacober SJ, Hoevelmann U, Plum-Moerschel L, Watkins E, Gastaldelli A, Heise T.
  Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
  DIABETES OBES METAB 19: 482-488, 2017
• Heise T, Zijlstra E, Nosek L, Heckermann S, Plum-Mörschel L, Forst T.
  The euglycaemic glucose clamp: What it can and cannot do - and how to do it.
  DIABETES OBES METAB 18: 972-982, 2016
• Forst TA, Plum-Mörschel L, Heise T.
  Pharmacological intervention in type 2 diabetes mellitus - A pathophysiologically reasoned approach?
  CURR DIABETES REV 2016 Jun 13. (Epub ahead of print)
• Sha S, Polidori D, Farrell K, Ghosh A, Natarajan J, Vaccaro N, Pinheiro J, Rothenberg P, Plum-Mörschel L.
  Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
  DIABETES OBES METAB 17: 188-197, 2015
• Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, Sica D, Rothenberg P, Plum-Mörschel L.
  Effect of the sodium glucose co-transporter 2 inhibitor, canagliflozin, on plasma volume in patients with type 2 diabetes mellitus.
  DIABETES OBES METAB 2014, Jun 17. doi:10.1111/dom.12322 (Epub ahead of print)
• Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P.
  Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
  J CLIN ENDOCRINOL METAB 98: E867-871, 2013

Browse Profil's list of publications to see our other publications.

Selected Achievements and Work Experience